Infertility is a growing global issue, with estimates indicating that around 17.5% of couples of reproductive age (source: WHO, 2023) face difficulties conceiving. Current treatments, such as in vitro fertilization (IVF), although effective, often involve long waiting times, high costs, and a significant physical and emotional burden on patients. In this context, stem cell research offers new perspectives for making solutions more accessible and less invasive for those who wish to have a child.
Stem cell research is opening horizons that were unimaginable just a few years ago. The latest confirmation comes from the United States, where the FDA has recently approved a Phase 3 clinical trial for Fertilo, a therapy based on induced pluripotent stem cells (iPSCs) developed by Gameto. This marks a historic moment for regenerative medicine, demonstrating the revolutionary potential of iPSCs in addressing medical needs that still lack effective solutions.
The evolution of science in fertility
Induced pluripotent stem cells are one of the most remarkable discoveries in modern biology. Thanks to the pioneering work of Shinya Yamanaka, we now know that adult cells can be reprogrammed and returned to an embryonic-like state, with the ability to differentiate into any cell type. This technology represents a breakthrough in regenerative medicine and also holds promising applications in fertility.
Fertilo leverages the potential of iPSCs to optimize the oocyte maturation process, reducing the need for high-dose hormonal stimulation. Traditionally, an in vitro fertilization (IVF) cycle requires 10 to 14 days of hormone injections to mature the eggs. With Fertilo, this process is drastically reduced to 2–3 days, cutting the number of required hormone injections by 80%.
A less invasive and more effective approach
This technology not only simplifies the assisted reproduction process but also significantly reduces the risks associated with hormonal stimulation, such as ovarian hyperstimulation syndrome. Traditional methods can cause important side effects, whereas Fertilo enables a more natural maturation of oocytes by using young, engineered ovarian support cells.
The significance of this innovation is confirmed by the first human birth achieved using Fertilo technology, which took place in December 2024 at the Clínica Santa Isabel in Lima, Peru. This result not only represents a scientific milestone but also demonstrates how biotechnology can offer new possibilities for millions of people facing fertility challenges.
Regenerative medicine in service of reproduction
Induced pluripotent stem cells are transforming reproductive medicine. It is not only about improving the success rates of in vitro fertilization, but about completely rethinking how we approach fertility. Gameto has announced that the Phase 3 clinical trial of Fertilo will involve 15 centers across the United States, collecting crucial data to assess the effectiveness and safety of this technology.
Beyond fertility, Gameto’s platform is exploring applications of iPSCs in other areas, such as menopause and ovarian cancer. The use of reprogrammed stem cells could represent the key to safer and more effective treatments in the field of women’s health.
A future of possibilities
The path opened by Fertilo shows that iPSCs are no longer just a theoretical promise, but a concrete reality. The field of regenerative medicine is making giant strides, and the use of induced pluripotent stem cells could redefine not only assisted reproduction but the entire approach to treating diseases related to cellular aging.
The FDA approval marks a turning point: the first Phase 3 clinical trial for an iPSC-based therapy in the United States is not only an achievement for Gameto, but for the entire scientific community working to turn the medicine of the future into an accessible reality for all.
EternaCell is committed to making the most advanced solutions in regenerative medicine accessible, offering its clients the opportunity to preserve their cells today for the treatments of tomorrow.